Welcome to the PharmCast Research Store. Gain access to market leading research in your industry. You can browse through the portfolio of reports below or enter keywords in the search box to find the information you have been looking for.
  • Browse Reports & Briefs
  • Browse Company Profiles
  • Browse Industry Profiles
  • Latest News
Number of Employees

< 250 (30)

250 - 999 (22)

1,000 - 2,499 (20)

2,500 - 4,999 (29)

5,000 - 9,999 (56)

10,000 - 49,999 (113)

50,000+ (40)

Annual Revenue US$m

< 50 (19)

50 - 99 (7)

100 - 199 (8)

200 - 499 (20)

500 - 999 (11)

1,000 - 1,999 (45)

2,000+ (189)

Top stories

Air Methods Q1 net income increases

Air Methods Corporation has reported that income from continuing operations for the first quarter ended March 31, 2015 was $12.88 million, or $0.32 per share, compared to $11.58 million, or $0.29 per share, for the same quarter ended March 31, 2014...more >>

US Physical Therapy Q1 net income decreases

US Physical Therapy, Inc. has reported that net income attributable to common shareholders for the first quarter ended March 31, 2015 was $4.17 million, or $0.34 per share, compared to $4.23 million, or $0.27 per share, for the same quarter ended March 31, 2014...more >>

Sequenom reports net earnings for Q1

Sequenom, Inc., a molecular diagnostic testing and genetics analysis company, has reported that net earnings for the first quarter ended March 31, 2015 were $14.28 million, or $0.11 per diluted share, compared to a net loss of $15.67 million, or $0.13 loss per diluted share, for the same quarter ended March 31, 2014...more >>

Mallinckrodt reports higher Q2 net income, raises guidance for 2015

Mallinckrodt plc, a biopharmaceutical company, has reported that net income for the second quarter ended March 27, 2015 was $98.8 million, or $0.84 per diluted share, compared to $11.6 million, or $0.20 per diluted share, for the same quarter ended March 28, 2014. For 2015, the company expects adjusted earnings per diluted share to be in the range of $7.10 to $7.50, compared to the prior guidance of $6.70 to $7.20...more >>

More headlines

Aeterna Zentaris Q1 net loss increases
Published 22 May 2015 - MarketLine

Alnylam Pharmaceuticals Q1 net loss decreases
Published 22 May 2015 - MarketLine

Alliance HealthCare reports lower Q1 net income, provides annual outlook
Published 22 May 2015 - MarketLine

Portola Pharmaceuticals Q1 net loss increases
Published 22 May 2015 - MarketLine

MannKind Q1 net loss decreases
Published 22 May 2015 - MarketLine

Theravance Biopharma reports lower Q1 net loss, provides annual outlook
Published 22 May 2015 - MarketLine

Ascom introduces nurse call portfolio in Australia and New Zealand
Published 22 May 2015 - MarketLine

Asterias Biotherapeutics Q1 net loss increases
Published 22 May 2015 - MarketLine

Novavax Q1 net loss increases
Published 22 May 2015 - MarketLine

Stada Arzneimittel Q1 net income decreases
Published 22 May 2015 - MarketLine

Sigma-Aldrich Q1 net income remains flat
Published 22 May 2015 - MarketLine

Browse all news >>